Vaccines for the Prevention of COVID-19: An Unprecedented Need: An Unprecedented Response

Susan J. Little, MD
Professor of Medicine
Division of Infectious Diseases and Global Public Health
Co-Director of the Antiviral Research Center
University of California San Diego, CA



VIDEOTop of page

PRN no longer offers CME or ABIM MOC.Top of page

About the Presenter:Top of page

Susan Little, MD is the Director of the UCSD Primary Infection Research Program, Director of the UCSD AIDS Clinical Trials Group Clinical Research Site, and Co-Director of the UCSD Antiviral Research Center. Dr. Little’s research interests include the pathogenesis, prevention, and treatment of acute and very recent HIV infection and the use of molecular epidemiologic methods to infer and characterize HIV transmission networks. She also studies factors that contribute to HIV transmission and novel diagnostic strategies to identify acutely infected individuals. She is actively involved in the training and mentoring of students, post-doctoral research fellows, and junior faculty. She is an investigator of the UCSD Center for AIDS Research (CFAR) and chairs the CFAR Ending the HIV Epidemic Scientific Working Group. She has recently taken an active role in the COVID-19 Prevention Network (CoVPN), leading Phase IIIefficacy trials for COVID-19 vaccines and monoclonal antibodies.

Learning Objectives: Top of page

At the completion of this educational session, learners will:

  • Understand the safety and efficacy of the Moderna and Pfizer derived from US Phase 3 clinical trials.
  • Know how to counsel patients on the risks and benefits of receiving these mRNA vaccines.
  • Be able to report adverse experiences in your patient population during post-licensure surveillance.
  • Understand how current limitations in available data shape ongoing recommendations for nonpharmacologic interventions.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

You must be logged in to post a comment. Login | Register